Company Overview
Neuland Laboratories Limited (Scrip Code: 524558, NSE: NEULANDLAB) is a global CDMO focused on API development and manufacturing across generic and innovator programs. The company reported exceptional FY 2025-26 performance with significant growth across financial, operational, and ESG metrics.
Financial Performance Highlights
FY 2025-26 Financial Results:
- Total Income: ₹2,053.15 crore (37.1% YoY growth from ₹1,497.35 crore)
- EBITDA: ₹603.41 crore (76.0% YoY growth from ₹342.80 crore)
- EBITDA Margin: 29.4% (improved from 22.9%)
- Profit After Tax: ₹363.11 crore (40.0% YoY growth from ₹259.43 crore)
- EPS: ₹283.01 per share
- R&D Investment: ₹79.2 crore (29% YoY increase)
Balance Sheet Strength:
- Net Worth: ₹1,864.98 crore
- Cash Balances: ₹353.6 crore
- Net Debt: Negative ₹156.8 crore
- Current Ratio: 2.06
- ROCE: 26.14%
Business Segment Performance
Generic Drug Substances (GDS): Below expectations with some shipment delays, though Prime APIs (Ezetimibe and Mirtazapine) and Specialty APIs performed well. Two new DMFs filed (Vonoprazan and Edoxaban).
Custom Manufacturing Solutions (CMS): Primary growth driver with strong momentum, featuring 98 active projects across development stages, supporting 4 approved NDAs and 27 IND filings to date.
Strategic Investments and Expansion
Peptide Manufacturing Facility: ₹254 crore investment to expand peptide synthesiser reactor capacity from 0.5 KL to 6.37 KL, on track for commissioning in FY 2026-27 with clear visibility into initial utilization programs.
New R&D Centre: ₹190 crore investment in Genome Valley, Hyderabad, comprising 135,000-140,000 sq. ft. purpose-built campus expected to significantly strengthen technology platform.
Manufacturing Capacity: Total API manufacturing capacity of 1,226 kL with 52 KL new manufacturing block added during the year across three USFDA-approved manufacturing units.
ESG and Sustainability Performance
Key Milestones: SBTi validation of near-term and net-zero targets, CDP ratings: A for Water Security and B for Climate Change, S&P Global ESG Score: 76 (improved from 70), and EcoVadis Silver Medal (91st percentile globally).
Environmental Performance: Zero Liquid Discharge status maintained across all facilities, 99.9% hazardous waste co-processed/reused, 100% zero waste to landfill, water consumption of 188,097.65 m³, and GHG Emissions of 223,173.26 tCO2e.
Social Initiatives: CSR expenditure of ₹6.09 crore, 450+ employees contributed 2,920 volunteering hours, women representation of 11.97% in permanent workforce, zero fatalities and zero lost time injuries, and 1.42 lakh+ training hours delivered.
Regulatory and Compliance
Global Regulatory Presence: 75 active US DMFs, 17 DMFs filed with China, ~499 EUDMF filings across European markets, 30 CEPs received, and total global filings exceeding 1,000.
Quality and Compliance: All manufacturing locations undergo regulatory audits annually, Unit II completed USFDA inspection in 2025, over 80 customer audits conducted with no critical observations, and ISO 9001:2015 certification across all manufacturing sites.
Leadership and Governance
Board Changes: Dr. Christopher Cimarusti passed away on February 28, 2026; Dr. Ravi Gopinath appointed as Independent Director effective August 1, 2025; Dr. Mauricio Futran appointed as Additional Non-Executive Director effective May 12, 2026.
Management Transition: Mr. Davuluri Sucheth Rao transitioned to Executive Vice Chairman effective April 1, 2026; Mr. Davuluri Saharsh Rao appointed as CEO & Managing Director effective April 1, 2026.
Dividend and Corporate Actions
The Board recommended a final dividend of ₹34 per equity share (340%) for FY 2025-26, subject to shareholder approval at the 42nd AGM scheduled for August 2026. The dividend payout ratio is approximately 12.01% of PAT.
Foreign Currency Exposure and Risk Management
Financial Assets and Liabilities: USD-denominated trade receivables increased to ₹42.94 crore (FY25: ₹22.38 crore) with a 5% USD rate change impacting PBT by ₹1.87 crore. The company maintains comprehensive currency sensitivity analysis and risk management protocols.
Outlook and Future Strategy
The company is evolving into a more innovation-led and globally integrated CDMO platform. The CMS business is entering its next growth phase supported by recently commercialized molecules and a robust pipeline. Investments in peptide capabilities and the new R&D center are expected to enable participation in higher-value innovation-driven programs, positioning Neuland for sustained future growth.